Gilead Sciences Inc   (GILD)
Other Ticker:  
Price: $77.0900 $-0.56 -0.721%
Day's High: $78.62 Week Perf: -1.95 %
Day's Low: $ 77.01 30 Day Perf: -7.73 %
Volume (M): 5,439 52 Wk High: $ 89.74
Volume (M$): $ 419,293 52 Wk Avg: $74.71
Open: $78.00 52 Wk Low: $57.17

 Market Capitalization (Millions $) 97,210
 Shares Outstanding (Millions) 1,261
 Employees 14,400
 Revenues (TTM) (Millions $) 27,043
 Net Income (TTM) (Millions $) 5,539
 Cash Flow (TTM) (Millions $) 640
 Capital Exp. (TTM) (Millions $) 590

Gilead Sciences Inc
Gilead Sciences,'Inc. is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. We have six products that are currently marketed in the U.S., all of which are also marketed in other countries worldwide. Our research and clinical programs are focused on anti-infectives, including antivirals and antifungals. We endeavor to grow our existing portfolio of products through proprietary clinical development programs, internal discovery programs and an active product acquisition and in-licensing strategy.

   Company Address: 333 Lakeside Drive Foster City 94404 CA
   Company Phone Number: 574-3000   Stock Exchange / Ticker: NASDAQ GILD
   GILD is expected to report next financial results on August 07, 2023.

Customers Net Income grew by GILD's Customers Net Profit Margin grew to

23.48 %

3.14 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV   -5.2%    
ABT   -5.56%    
BMY   -3.07%    
JNJ   -2.87%    
LLY   -3.75%    
PFE        2.26% 
• View Complete Report

Agilent Technologies Inc

Reasonable result at Agilent Technologies Inc over the financial second quarter of 2023

Agilent Technologies Inc, a Biotechnology and Pharmaceuticals company has released its financial results for the three months ending April 30, 2023. The company's revenue increased by 6.845% to $1.72 billion as compared to $1.61 billion on a year-over-year basis. Meanwhile, the company's profitability showed significant improvement, with profits rising 12.09% to $1.02 from $0.91 in the prior year reporting season.
However, there was a decrease in revenue by -2.221% from $1.76 billion in the preceding period, and profits also fell by -14.29% from $1.19 per share. Despite these reductions, earnings rose by 10.22% from net earnings of $274.000 million reported in the second quarter of the 2023 earnings season a year ago.

Steris Plc

The Biotechnology and Pharmaceuticals company has failed to turn into profitability despite the epic Surge in revenue in the fourth quarter of 2023

Steris Plc, a leading biotechnology and pharmaceuticals company, has announced a significant increase in revenue for the most recent fiscal period. The company reported a year-on-year revenue rise of 311.172% to $2.94 billion, which is an impressive figure. However, the company slipped into a net loss of $-0.60. This news is significant and has caused some concern among investors and stakeholders.
Compared to the preceding quarter, the income per share fell from $0.56 per share. On the other hand, revenue doubled by a substantial 322.827% from $696.24 million. In the fourth quarter of 2023, Steris Plc posted a net loss of $-90.386 million, as opposed to the net proceeds of $73.623 million recorded in the same quarter a year before. This decline in profits is concerning and indicates a downward trend.

Burzynski Research Institute Inc

The emerging corporation from the Biotechnology and Pharmaceuticals market the Burzynski Research Institute Inc issued the fourth quarter of 2023, results

As a journalist who closely follows the financial performance of various corporations, I find the latest results from Burzynski Research Institute Inc quite intriguing. This small biotech and pharmaceutical firm has reported an operating deficit of $-0.215998 million for the fourth quarter of 2023. While the company has not yet revealed its revenue figures, it is worth comparing these results with the corresponding period from the previous year.
In the fourth quarter of 2022, Burzynski Research Institute Inc had already reported an operating deficit of $-0.131272 million. The fact that the shortfall has further expanded to $-0.216 million in the same quarter of 2023 suggests that the company is going through a turbulent period. However, it's important to note that many businesses face such choppy phases while they try to establish prosperous revenue sources.

Immunovant Inc

The Biotechnology and Pharmaceuticals company announced Revenue of $4.098 million, in the financial fourth quarter of 2023

Immunovant Inc, a clinical stage biopharmaceutical company, has reported their financial results for the fiscal period ending March 31, 2023. According to the report, the company generated revenue of $4.098 million, which is a positive sign.
However, the company also reported a net loss of $59.432 million for the same period, higher than the previous year's loss of $47.171 million. The net loss per share has worsened from $1.43 in the previous fiscal year to $1.71 in this fiscal year, indicating that the company is facing some financial challenges.

Replimune Group Inc

Replimune Group Inc announced operating loss of $-52.995 million, in the fourth quarter of 2023 financial report

Replimune Group Inc is a biotechnology company that focuses on developing cancer therapies based on the use of oncolytic viruses. The company's goal is to develop a range of therapies that can be used in combination with other cancer treatments to improve patient outcomes.
The recent earnings announcement by Replimune Group Inc has raised concerns among investors, who are worried about the company's current financial situation. The $52.995 million operating loss for the most recent fiscal period is a cause for concern, particularly as the company is expected to report further losses in the coming months.


Gilead Sciences Inc's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
HIV products Total
 Segment     of total Revenue
 Segment     of total Revenue
Other products
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Complera Eviplera
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Gilead Sciences Inc announced annual revenue outlook on

Earnings Outlook
Gilead Sciences Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States
Other European countries
Other countries


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071